Effect of parathyroid hormone administration in a patient with severe hypoparathyroidism caused by gain-of-function mutation of calcium-sensing receptor

Endocrine Journal

Volumn 53, Issue 6, 2006, Pages 797-802

  Shiohara, Masaaki ^a   Shiozawa, Riyo ^a   Kurata, Kenji ^a   Matsuura, Hiroki ^a   Arai, Fumi ^a   Yasuda, Toshiyuki ^b   Koike, Kenichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION CHIBA MEDICAL CENTER   (Japan)

Author keywords

Hypocalcemia; Magnesium; Phosphate; Vitamin D3

Indexed keywords

CALCIUM; CALCIUM SENSING RECEPTOR; CREATININE; CYCLIC AMP; PARATHYROID HORMONE[1-34]; PHOSPHATE;

ARTICLE; CALCIUM BLOOD LEVEL; CASE REPORT; DISEASE SEVERITY; DRUG EFFECT; GENE MUTATION; HUMAN; HYPOPARATHYROIDISM; KIDNEY TUBULE; MAGNESIUM BLOOD LEVEL; MALE; PHOSPHATE URINE LEVEL; SCHOOL CHILD;

CALCIUM; CHILD; CREATININE; CYCLIC AMP; HUMANS; HYPOPARATHYROIDISM; MAGNESIUM; MALE; MUTATION; PARATHYROID HORMONE; PHOSPHORUS; RECEPTORS, CALCIUM-SENSING; TERIPARATIDE;

EID: 33845980600     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-053     Document Type: Article

References (28)

1. 2+-sensing receptor from bovine parathyroid. Nature 366: 575-580.
2. Chattopadhyay N, Mithal A, Brown EM (1996) The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr Rev 17: 289-307.
3. Riccardi D, Park J, Lee WS, Gamba G, Brown EM, Hebert SC (1995) Cloning and functional expression of a rat kidney extracellular calcium-sensing receptor. Proc Natl Acad Sci USA 92: 131-135.
4. Bai M, Quinn S, Trivedi S, Kifor O, Pearce SHS, Pollak MR, Krapcho K, Hebert SC, Brown EM (1996) Expression and characterization of inactivating and activating mutations in the human Ca2+o-sensing receptor. J Biol Chem 271: 19537-19545.
5. Baron J, Winer KK, Yanovski JA, Cunningham AW, Laue L, Zimmerman D, Cutler GB Jr (1996) Mutations in the Ca2+-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism. Hum Mol Gen 5: 601-606.
6. Shiohara M, Mori T, Bai M, Brown EM, Watanabe T, Yasuda T (2004) A novel gain-of-function mutation (F821L) in the transmembrane domain of calcium-sensing receptor is a cause of severe sporadic hypoparathyroidism. Eur J Pediatr 163: 94-98.
7. Okazaki R, Chikatsu N, Nakatsu M, Takeuchi Y, Ajima M, Miki J, Fujita T, Arai M, Totsuka Y, Tanaka K, Fukumoto S (1998) A novel activating mutation in calcium-sensing receptor gene associated with a family of autosomal dominant hypocalcemia. J Clin Endocrinol Metab 84: 363-366.
8. Yamamoto M, Akatsu T, Nagase T, Ogata E (2000) Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: Is it possible to differentiate the two disorders? J Clin Endocrinol Metab 85: 4583-4591.
9. Watanabe S, Fukumoto S, Chang H, Takeuchi Y, Hasegawa Y, Okazaki R, Chikatsu N, Fujita T (2002) Association between activating mutations of calcium-sensing receptor and Bartter's syndrome. Lancet 360: 692-694.
10. Chan JCM, Young RB, Alon U, Mamunes P (1983) Hypercalcemia in children with disorders of calcium and phosphate metabolism during long-term treatment with 1,25 dihydroxyvitamin-D3. Pediatrics 72: 225-233.
11. Santos F, Smith JV, Chan JCM (1986) Hypercalciuria associated with long-term administration of calcitriol (1,25-dihydroxyvitamin D). Am J Dis Child 140: 139-142.
12. Weber G, Cazzuffi MA, Frisone F, deAngelis M, Pasolini D, Tomaselli V, Chiumello G (1988) Nephrocalcinosis in children and adolescents: sonographic evaluation during long-term treatment with 1,25-dihydrocholecalciferol. Child Nephrol Urol 89: 273-276.
13. Sato K, Hasegawa Y, Nakae J, Nanao K, Takahashi I, Tajima T, Shinohara N, Fujieda K (2002) Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. J Clin Endocrinol Metab 87: 3068-3073.
14. Igarashi T, Yamamoto M, Yamada M, Ogata T, Katsuragi S (1982) Application of newly synthesized 1-34 human parathyroid hormone for diagnostic tests. Pharmatherapeutica 3: 79-85.
15. Dempster DW, Cosman F, Kurland ES, Zhou H, Nieves J, Woelfert L, Shane E, Plavetic K, Muller R, Bilezikian J, Lindsay R (2001) Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J Bone Min Res 16: 1846-1853.
16. Koch CA (2001) Rapid increase in bone mineral density in a child with osteoporosis and autoimmune hypoparathyroidism treated with PTH 1-34. Exp Clin Endocrinol Diab 109: 350-354.
17. Retraction in: Exp Clin Endocrinol Diab (2002) 110: 100.
18. Winer KK, Yanovski JA, Cutler GB (1996) Synthetic human parathyroid hormone 1-34 vs. calcitriol and calcium in the treatment of hypoparathyroidism: results of a randomized crossover trial. J Am Med Assoc 276: 631-636.
19. (2+)-sensing receptor gene mutation. Nat Genet 8: 303-307.
20. Pearce SHS, Williamson C, Kifor O, Bai M, Coulthard MG, Davis M, Lewis-Barned N, McCredie D, Powell H, Kendall-Taylor P, Brown EM, Thakker RV (1996) A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor. New Engl J Med 335: 1115-1122.
21. Watanabe T, Bai M, Lane CR, Matsumoto S, Minamitani K, Minagawa M, Niimi H, Brown EM, Yasuda T (1998) Familial hypoparathyroidism: Identification of a novel gain of function mutation in transmembrane domain 5 of the calcium-sensing receptor. J Clin Endocrinol Metab 83: 2497-2502.
22. De Luca F, Ray K, Mancillia EE, Fan GF, Winer KK, Gore P, Spiegel AM, Baron J (1997) Sporadic hypoparathyroidism caused by de novo gain-of-function mutations of the Ca2+-sensing receptor. J Clin Endocrinol Metab 82: 2710-2715.
23. Lienhardt A, Bai M, Lagarde J-P, Rigaud M, Zhang Z, Jiang Y, Kottler M-L, Brown EM, Garabedian M (2001) Activating mutations of the calcium-sensing receptor: management of hypocalcemia. J Clin Endocrinol Metab 86: 5313-5323.
24. Winer KK, Yanovski JA, Sarani B, Cutler GB (1998) A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism. J Clin Endocrinol Metab 83: 3480-3486.
25. O'Rourke JN Jr, Booth BH, Patterson R (1973) An anaphylactic reaction to parathyroid hormone. J Allergy Clin Immunol 52: 55-59.
26. Vahle JL, Sato M, Long GG Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30: 312-321.
27. Sato M, Vahle J, Schmidt A Westmore M, Smith S, Rowley E, Ma LY (2002) Abnormal bone architecture and biomechanical properties with near-lifetime treatment of rats with PTH. Endocrinology 143: 3230-3242.
28. Winer K, Ko CW, Reynolds JC, Dowdy K, Keil M, Peterson D, Gerber LH, McGarvey C, Cutler GB (2003) Long-term treatment of hypoparathyroidism: A randomized controlled study comparing parathyroid hormone-(1-34) with calcitriol and calcium. J Clin Endocrinol Metab 88: 4214-4220.